click below
click below
Normal Size Small Size show me how
Hospital Meds
| Term | Definition |
|---|---|
| Acetaminophen; Class Trade Name | -Non narcotic analgesic, antipyretic |
| Acetaminophen; Description Indications | -Elevates the pain threshold in the CNS, and acts on the hypothalamic thermoregulatory centers decreasing temperature -fever and mild to moderate pain |
| Acetaminophen; Contraindications | 1. hypersensitivity 2.hepatitis, hepatic/renal dysfunction 3.alchoholism 4.anemia |
| Acetaminophen; Side effects | - Dizziness, anaphylactic reaction, epidermal reactions, hepatic failure, renal failure, thrombocytopenia, diaphoresis and chills |
| Acetaminophen; Administration Onset /Duration | Adult: 325-650 mg PO q 4-6 hrs, 650 mg PR q 4-6 hrs (max 4g/day) Pediatric: 15 mg/kg q 4-6 hrs (PO or PR) (max 2.6 g/day) -30-60 min, 3-4 hrs |
| Insulin; Class Trade names | -Hormone, Hypoglycemic agent -NPH, Humulin, Novolin, Novolog |
| Insulin; Indications | 1. Diabetic Ketoacidosis 2. Patients with severely high BG levels 3. Hyperkalemia |
| Insulin; Contraindications | 1. Hypoglycemia 2. Caution in hypokalemia |
| Insulin; Side Effects | 1.Allergic reactions 2.Headache 3.Hypoglycemia 4.Hypokalemia |
| Insulin; Administration Onset/Duration | Adult/Peds: 10-25 units SQ. Infuse: 0.1 U/kg/hr IV 30 minutes- 1 hr; 2-3 hrs |
| Meperidine Hydrochloride; Class Trade name | -Opioid Analgesic, CNS depressant, Schedule 2controlled substance -Demerol |
| Meperidine Hydrochloride; Description | Depresses pain perception by acting on the opioid receptor in the CNS |
| Meperidine Hydrochloride; Indication | Moderate to severe pain |
| Meperidine Hydrochloride; Contraindications | Hypersensitivity MAO inhibitors within 2 weeks Head injury Abdominal Pain of unknown etiology Hypovolemia |
| Meperidine Hydrochloride; Side Effects | Headache, CNS depression, Respiratory/Cardiovascular Depression, Dry mouth/nausea/vomiting, Flushing/Uticaria/Diaphoresis/Pruitus, Constipation, QT prolongation, Constipation, Pupil constriction(Miosis) |
| Meperidine Hydrochloride; Administration Onset/Duration | Adult: IV 25-50 mg. IM 50-100 mg Pediatrics: 1 mg/kg 5 min IV, 10 min IM; 2-4 hrs |
| Hydromorphone; Class Trade Name | -Synthetic opioid analgesic, CNS depressant, Schedule 2 controlled substance. - Dilaudid |
| Hydromorphone; Description | Centrally acting analgesic that binds to the opiate receptor sites in the CNS. Suppresses cough via suppression of the medulla. |
| Hydromorphone; Indications | Moderate to severe pain. Antitussive. |
| Hydromorphone; Contraindications | 1. Hypersensitivity 2. Head injury 3. Abdominal pain 4. Hypovolemia |
| Hydromorphone; Side Effects | 1. Headache 2. CNS depression 3. Respiratory/Cardiovascular Depression 4. Dry mouth/nausea/vomiting 5. Flushing/uticaria/diaphoresis/pruritus 6. Constipation 7. QT prolongation 8. Pupil constriction (miosos) |
| Hydromorphone; Administration Onset/Duration | Adult: IV 1 mg followed by .5-1 mg q 3-5 min prn IM 2-4 mgq 3-4 hrs. Pediatrics: not recommended - 2-3 min, 3-6 hrs |
| TDaP: | Tetanus toxoid and reduced Diptheria toxoid and Acellular Pertussis |
| TDap; Class Trade Name | - Vaccine Combo - Adacel, Boostrix, Tdap |
| TDaP; Description | Stimulates active immunity to diphtheria, tetanus, and pertussis toxins due to antibody production following exposure to the weakened toxins in the vaccine. |
| TDaP; Indications | Initial vaccination is recommended for all individuals to prevent infection with tetanus, diphtheria, and pertussis. Boosters are recommended every 5-10 years and with each pregnancy. |
| TDaP; Tetanus (lockjaw) | Enviornmentally prevalent bacterium that produces toxins that lead to severe tonic muscle spasms. Early spasms typically effect jaw, face and neck. Full body spasms cause fractures, muscle/tendon rupture, and death from respiratory paralysis. |
| TDaP; Diphtheria | Highly contagious respiratory infection that causes a thick pseudomembrane to form on the lining of the airway passages. Can cause fatal asphyxiation. |
| TDaP; Pertussis (Whooping Cough) | Highly contagious respiratory infection causing upper respiratory symptoms and severe bronchitis with a severe cough. Can cause fatal respiratory failure. |
| TDaP; Contraindications | 1. Anaphylactic reaction to a prior dose, or any of the components. 2. Encephalopathy within 7 days of a previous dose. |
| TDaP; Side Effects | 1. Swelling, redness, rash and pain at injection site 2. Nausea, vomiting, and diarrhea 3. Fever, Chills, body aches, muscle weakness 4. Headache 5. Seizure |
| TDaP; Administration | 0.5 mL IM (typically in the deltoid) |